15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering BioAge Labs, Inc, 7 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $12.00 to $73.00 (about 6.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $46.25 sits 405% above the current $9.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.63 next quarter toward $-2.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy788%
Hold113%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to BioAge Labs, Inc.
As of Sep, 7 of 8 firms rate BIOA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BIOA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.63
Range $-0.76 – $-0.42 · 7 analysts · -13% YoY
Next period, 7 analysts expect BioAge Labs, Inc to earn $-0.63 a share (range $-0.76 – $-0.42), versus $-0.72 a year earlier. Full-year consensus is $-2.37, growing to $-2.36 the year after.
REVENUE · NEXT QUARTER
$1.3M
Range $0 – $3.1M · 7 analysts · -59% YoY
Revenue is expected to reach $1.3M (range $0 – $3.1M), -58.8% year-over-year. Full-year consensus is $7.6M, rising to $15.7M next year.
Top analysts covering BioAge Labs, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIOA.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Hold
$12.00+31.0% to target
Overall win rate
64%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$21.00+129.3% to target
Overall win rate
43%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$73.00+696.9% to target
Overall win rate
33%
+ Follow
#4
Joseph Stringer
Needham · Rank #195
Buy
$35.00+282.1% to target
Overall win rate
36%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #360
Buy
$50.00+445.9% to target
Overall win rate
33%
+ Follow
BIOA stock forecast FAQ
What is BIOA's average 12-month price target?+
The 8 analysts with a live target average $46.25 for BioAge Labs, Inc over the next 12 months, ranging from a $73.00 high to a $12.00 low.
Is BIOA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 7 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BIOA?+
The Street-high target is $73.00 (Piper Sandler), and the Street-low is $12.00 (Morgan Stanley). The average of all 8 active targets is $46.25.
How many Wall Street analysts cover BIOA?+
8 analysts have an active rating on BioAge Labs, Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering BIOA?+
Among analysts who currently cover BIOA, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Hold with a $12.00 target.
What is BioAge Labs, Inc's projected EPS for next quarter?+
The consensus estimate is $-0.63 per share (range $-0.76 – $-0.42) across 7 analysts. Full-year EPS is projected at $-2.37, rising to $-2.36 the following year.
How much revenue is BioAge Labs, Inc expected to report next quarter?+
Consensus revenue is $1.3M (range $0 – $3.1M). Full-year revenue is projected at $7.6M, growing to $15.7M next year.
Have analysts been upgrading or downgrading BIOA lately?+
As of Sep, 7 of 8 firms rate BIOA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIOA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
